DelveInsight’s “Neuroblastoma Market Insights, Epidemiology, and Market Forecast-2032” report provides an in-depth understanding of neuroblastoma, historical and forecast epidemiology, and neuroblastoma market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.
The Neuroblastoma market is expected to rise due to the increasing prevalence and awareness of the disease over the forecast period. Furthermore, the launch of various multi-stage neuroblastoma pipeline products will significantly revolutionize the dynamics of the neuroblastoma market.
Overview of Neuroblastoma
Neuroblastoma is an embryonic malignant tumor of the sympathetic nervous system resulting from neuroblasts (sympathetic pluripotent cells). It is derived from two words i.e. ‘neuro’ means nerves and ‘blastoma’ refers to the tumor affecting immature or developing cells. It originates in the adrenal medulla and paraspinal or periaortic regions where sympathetic nervous system tissue is present.
The stages of neuroblastoma determine how far the tumor has spread in patients, and the disease is staged based on the results of physical exams, imaging tests, and biopsies of the main tumor and other tissues.
Some of the key facts from the Neuroblastoma Market report:
- Neuroblastoma Market Size is Expected to Grow with Significant CAGR over the Study Period (2019-2032)
- In December 2021hu14.18K322A phase II data published in ASCO journal, data showed improved outcomes in children with newly diagnosed high-risk neuroblastoma treated with chemoimmunotherapy
- In September 2021Y-mAbs Therapeutics Presented Data from Phase II Trial of Naxitamab for the Treatment of Refractory/Relapsed High-Risk Neuroblastoma
- According to a study by Shohet et al., the median time to relapse is approximately 1.5 years from diagnosis
- Leading Neuroblastoma Companies: Clarity Pharmaceuticals, Y-mabs Therapeutics, Eli Lilly, LaboratorioElea Phoenix, KC Pharmaceuticals, AutolusTherapeutics and others
- Key therapies for neuroblastoma: 67Cu-SARTATE, Omburtamab, LY 3295668, Racotumomab, Eflornithine, AUTO6NG and others
- Gender-based neuroblastoma epidemiology analyzed that neuroblastoma affects men slightly more than women
Get Free Sample for Neuroblastoma Market Report
Key Highlights of the Neuroblastoma Market Report:
- Neuroblastoma market report covers descriptive overview and comprehensive overview of Neuroblastoma and Neuroblastoma epidemiology market in 7MM (US, EU5 (Germany, Spain, France, Italy, UK) and Japan .)
- The Neuroblastoma market report provides information on current and emerging therapies.
- The Neuroblastoma market report provides historical and forecasted global market covering the diffusion of drugs in 7MM.
- The Neuroblastoma Market report provides an advantage which will help in developing business strategies by understanding the trends shaping and driving the Neuroblastoma market.
Learn More About Therapies Set to Capture Major Neuroblastoma Market Share @ Neuroblastoma Market Forecast
Segmentation of Neuroblastoma Epidemiology:
The Neuroblastoma market report offers epidemiological analysis for the study period 2019-2032 in 7MM segmented into:
- Total prevalence of neuroblastoma
- Prevalent cases of neuroblastoma by severity
- Prevalence by sex of neuroblastoma
- Diagnosed cases of episodic and chronic neuroblastoma
Neuroblastoma market
Neuroblastoma market dynamics are expected to change in the coming years owing to the expected launch of emerging therapies such as LY 3295668, Racotumomab, and others during the forecast period 2019-2032.
Download the report to understand what factors drive epidemiological trends in neuroblastoma @ Neuroblastoma Epidemiological Insights
Neuroblastoma Market Highlights
- Neuroblasts can cause due to immature cell growth or mutation of the gene responsible for controlling cell proliferation
- Rising cases of childhood cancer, increase in neuroblastoma treatment research and rising expenditure on cancer treatment are expected to drive the market growth over the forecast period
Neuroblastoma therapies and key companies
- 67Cu-SARTATE: Clarity Pharmaceuticals
- Omburtamab: Therapeutic Y-mabs
- LY 3295668: Eli Lily
- Racotumomab: Elea Phoenix Laboratory
- Eflornithine: KC Pharmaceuticals
- AUTO6NG: Autolus Therapeutics
Scope of the Neuroblastoma Market Report
- Study period: 2019-2032
- Cover: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Leading Neuroblastoma Companies: Clarity Pharmaceuticals, Y-mabs Therapeutics, Eli Lilly, LaboratorioElea Phoenix, KC Pharmaceuticals, AutolusTherapeutics and others
- Key therapies for neuroblastoma: 67Cu-SARTATE, Omburtamab, LY 3295668, Racotumomab, Eflornithine, AUTO6NG and others
- Therapeutic assessment of neuroblastoma: Currently Marketed Treatments for Neuroblastoma and Emerging Therapies for Neuroblastoma
- Neuroblastoma Market Dynamics: Neuroblastoma Market Drivers and Neuroblastoma Market Barriers
- Competitive intelligence analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG matrix, market entry strategies
- Unmet Needs, KOL Views, Analyst Views, Neuroblastoma Market Access and Reimbursement
Neuroblastoma Market Opportunities
- Understanding of neuroblastoma biology deepens, our therapeutic approaches for this disease continue to evolve
Contents
1. Introduction to Neuroblastoma Market Report
2. Executive Summary for Neuroblastoma
3. SWOT Analysis of Neuroblastoma
4. Share of Neuroblastoma Patients (%) Overview at a Glance
5. Neuroblastoma Market Overview at a Glance
6. Background and Overview of Neuroblastoma Disease
7. Neuroblastoma epidemiology and patient population
8. Neuroblastoma Patient Population by Countries
9. Current Neuroblastoma Treatment and Medical Practices
10. Unmet Needs of Neuroblastoma
11. Emerging therapies for neuroblastoma
12. Neuroblastoma Market Outlook
13. Neuroblastoma Market Analysis by Countries (2019-2032)
14. Access to the neuroblastoma market and reimbursement of therapies
15. Neuroblastoma Market Drivers
16. Neuroblastoma Market Barriers
17. Neuroblastoma Annex
18. Neuroblastoma Reporting Methodology
19. DelveInsight Abilities
20. Disclaimer
21. About DelveInsight
To learn more about treating neuroblastoma, visit @ Neuroblastoma Medications
Media Contact
Company Name: DelveInsight Business Research LLP
Contact person: Gaurav Bora
E-mail: Send an email
Call: 9193216187
Address:304 S. Jones Boulevard #2432
Town: Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/